- CEO
- Yong Qian Xu
- Full Time Employees
- 4,352
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- No. 788 Torch Street Nanchang JX China 330096
- IPO Date
- Sep 23, 1996
- Business
- Jiang Zhong Pharmaceutical Co.,Ltd Jiang Zhong Pharmaceutical Co.,Ltd (600750.SS) is a China-based company principally engaged in the research, development, production, and sale of Chinese patent medicines, over-the-counter (OTC) pharmaceuticals, health foods, and prescription drugs. The company offers a broad portfolio of OTC products covering spleen and stomach health such as stomach health tablets and Jianweixiaoshi tablets; intestinal tract care including lactic acid bacterin tablets/granules and bifidobacteria trifecta enteric capsules (Befeida); anorectal treatments; throat, cough, and asthma remedies like compound fresh bamboo extract and chuanbei loquat capsules; supplements and minerals such as multi-dimensional element tablets; and chronic disease management options. Its health consumer products encompass high-end nourishment, rehabilitation nutrition, gastrointestinal health, liver and gallbladder protection like pure liver tablets, dietary nutrition, basic vitamins, personal care essential oils, and probiotics; prescription drugs target heart and brain vascular conditions, chronic respiratory diseases, including cloprocaine hydrochloride injections and rabeprazole sodium enteric tablets; products are marketed under brands including Jiangzhong, Lihuo, Chuyuan, Shenlingcao, Yang Jisheng, and Songhai, primarily serving domestic markets in mainland China with headquarters in Nanchang, Jiangxi Province, where it was founded in 1969 and listed on the Shanghai Stock Exchange in 1996 as a subsidiary of China Resources Jiangzhong Pharmaceutical Group Co., Ltd. Recent developments include the controlling shareholder China Resources Jiangzhong cumulatively increasing its stake by 0.45% to 43.14% through open market purchases totaling RMB 61.29 million as of October 2025, further purchases adding 0.15% for RMB 19.75 million by April 2025, and agreements to acquire a 51% stake in Jiangxi Jiang Zhong Chinese Medicine Pieces Co., Ltd. as well as a proposed 70% equity interest in Jingcheng Huizhong Medicine; the company also earned recognitions such as inclusion in the Ministry of Industry and Information Technology's first batch of exemplary smart factories and digital navigation enterprise cases in early 2025, alongside stable 2025 performance with Q3 revenue of RMB 792 million despite a 6.3% yearly decline, and a net profit rise of 5.5% to RMB 683 million for the first three quarters.